07/21/2026
🔬💊 A common deworming drug is showing surprising promise in cancer research — here's what's actually known.
Mebendazole is an FDA-approved medication that's been used for decades to treat parasitic infections. But in recent years, researchers have discovered something unexpected: in laboratory studies, mebendazole has shown the ability to kill or slow the growth of cancer cells from a wide range of cancer types, including glioblastoma (brain), melanoma, ovarian, prostate, pancreatic, lung, and thyroid cancer. 🧬
How does it work? Researchers believe mebendazole disrupts microtubules (structures cells need to divide), triggers programmed cell death in cancer cells, and may even help block the blood supply tumors need to grow. It's a promising example of "drug repurposing" — finding new uses for existing, already-approved medications. 🔍
Here's the important context: this research is still in early stages. Most of these findings come from lab and animal studies, not large human trials. Some early-phase (Phase 1) human trials — including research on brain tumors — have shown mebendazole is safe and well-tolerated at certain doses, which is an encouraging first step. But safety data is not the same as proof that it treats cancer effectively in people. ⚠️
**This is not an approved cancer treatment**, and mebendazole should never be used to self-treat cancer outside of a supervised clinical trial. Anyone facing a cancer diagnosis should follow their oncologist's guidance and proven treatment protocols — early, promising research like this takes years of rigorous trials before it can become real-world care. 🩺
Still, it's a genuinely exciting glimpse into how existing medications might one day expand what's possible in cancer treatment. 🌱
💬 Had you heard about drug repurposing in cancer research before?
📌 Save this and share it with someone who follows medical research closely.
